NICE now allows Yescarta in specific cases for large B-cell lymphoma.- Gilead/Kite.
The National Institute for Health and Care Excellence announced that Yescarta (axicabtagene ciloleucel), from Gilead Sciences/Kite Pharma, will be available on the NHS to some adults with relapsed or refractory diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma. This CAR T-cell therapy will be offered to people whose disease has not responded after two or more rounds of chemotherapy or relapsed after a stem cell transplant.
In August 2018, NICE initially rejected the therapy for being too expensive, but since then a commercial deal between NHS England and Gilead group Kite has increased its potential cost effectiveness.
Related news and insights
Fabhalta is a Factor B inhibitor that acts proximally in the alternative complement pathway of the immune system, providing comprehensive control of red blood cell (RBC) destruction within and outside the blood vessels (intra- and extravascular hemolysis [IVH and EVH])
Merck KGaA, a leading science and technology company, announced that its two Phase III EVOLUTION clinical trials (evolution RMS 1 and evolution RMS 2) investigating the efficacy and safety of evobrutinib did not meet their primary endpoints of reducing annualized relapse rates (ARR) in people with relapsing multiple sclerosis (RMS) compared to oral teriflunomide (Aubagio) (0.11 vs. 0.11 in evolution RMS 1 and 0.15 for evobrutinib vs. 0.14 for teriflunomide in evolution RMS 2, p=NS in both trials)